Epub 2020/02/23
Fernandes AMAP, Landeira-Fernandez AM, Souza-Santos P, Carvalho-Alves PC, Castilho RF
Prior authorization denials rates for GLP-1 weight loss coverage have been documented as high as 60% in certain states, forcing patients to appeal decisions or seek alternative treatments
In the first trial, lixisenatide 20 g QD (n = 46) and liraglutide 1.2 (n = 44) and 1.8 mg QD (n = 46) were compared following 8 weeks treatment in 142 subjects with T2DM not adequately controlled with insulin glargine with or without metformin [17]
Both Wegovy and Mounjaro belong to a class of drugs known as GLP-1 agonists, which work by mimicking glucagon-like peptide-1 (GLP-1), a hormone that is in insulin secretion as well as how long food remains in your stomach, therefore having an impact on hunger, digestion and feelings of fullness
However, excess ROS can be pathological, and contribute to the development and progression of chronic diseases